Compiled By Jessica Oesterheld,
M.D.
This table is an abridged guide to CYPs and UGTs during pregnancy. To appreciate the full benefits of this information, click here to get a free 30-day trial version of GeneMedRx. This metabolism-based drug interaction software predicts response to medication combinations with optional input of genetic variations.
Last Update: May 16, 2008
Changes in Clearance |
| |
1st semester |
2nd semester |
3rd semester |
| CYP 1A2 |
reduced 33% |
reduced 49% |
reduced 65% |
| CYP2A6 |
|
increased 54% |
increased 54% |
| CYP2B6 |
|
|
|
| CYP2C8 |
|
|
|
| CYP2C9 |
no change |
no change |
increased 20% |
| CYP2C19 |
|
reduced 50% |
reduced 50% |
| CYP2D6 |
increased 26% |
increased 35% |
increased 48% |
| CYP2E1 |
|
|
|
| CYP3A4 |
increased 35-38% |
increased 35-38% |
increased 35-38% |
| UGT1A4 |
increased 200% |
increased 200% |
increased 300% |
| UGT2B7 |
|
|
indeterminate |
| acetylation |
indeterminate |
no change |
no change |
| xanthin oxidase |
no change |
no change |
no change |
GeneMedRx has not been reviewed or approved by the United States Food and Drug Administration and cannot be used to diagnose or treat any disease or other health condition.
